Skip to main content

Table 1 Main data needed at various time points for the IRYSS-COPD Appropriateness Study

From: The IRYSS-COPD appropriateness study: objectives, methodology, and description of the prospective cohort

Data needed at various time points
Evaluation in the ED
   Arterial blood gases parameters including PO2, PCO2 and pH.
   O2 saturation
   Presence of diabetes mellitus
   Presence of cardiovascular disease
   Expected adherence to treatment
   Response to previous treatments
   Severity of baseline COPD
   Number of hospital admissions in the year preceding the exacerbation
   Need for oxygen therapy at home
   Hemodynamic stability
   Level of consciousness, measured by the Glasgow Coma Scale [14]
   Presence of dyspnea at rest
   Exercise tolerance in the ED
   Respiratory rate
   Presence of paradoxical breathing or use of accessory respiratory musculature
   Sociodemographic information
Decision to admit or discharge home
   Arterial blood gases parameters including PO2, PCO2 and pH.
   O2 saturation
   Hemodynamic stability
   Level of consciousness, measured by the Glasgow Coma Scale[14]
   Presence of dyspnea at rest
   Respiratory rate
   Presence of paradoxical breathing or use of accessory respiratory musculature
If admitted, in the hospital
   Biological parameters such as arterial blood gases and blood glucose.
   Respiratory rate
   Presence of cardiac failure
   Results of chest x-ray
   Charlson Comorbidity Index[15]
   Medications prescribed for the acute episode and subsequent admission, methods of administration, and number of days of intravenous drug therapy.
   In-hospital morbidity and mortality: the appearance of complications, including all signs, symptoms, syndromes or diseases, that appeared or worsened during the hospital stay that were attributable to COPD or it treatment.
   Death
   Admission to an Intensive Care Unit (UCI) or to an Intermediate Respiratory Care Unit (IRCU); or need for Invasive Mechanical Ventilation (IMV) or Non-Invasive Mechanical Ventilation (NIMV)
   Length of stay
   General health status, from response to question 1 of the Short Form 36 (SF-36) questionnaire[16], degree of dyspnea, based on the Medical Research Council Dyspnea Index[17], and physical activity level (based on a scale employed previously in various studies at 1, and 7 days [18].
   Quality of life, measured by the EuroQol-5D questionnaire at 1, and 7 days [19, 20].
Follow-up on admitted patients (after hospital discharge and up to 60 days post-discharge)
   General health status, from response to question 1 of the Short Form 36 (SF-36) questionnaire[16], degree of dyspnea, based on the Medical Research Council Dyspnea Index[17], and physical activity level (based on a scale employed previously in various studies) [18].
   Quality of life, measured by the EuroQol-5D questionnaire [19, 20].
   Readmission within 30 days of the index exacerbation for the same reason, or readmission for any reason within 60 days after the index exacerbation
   Complications, including all signs, symptoms, syndromes or diseases that appeared or worsened during the 60-day observation period attributable to COPD or its treatment
   Variables collected from medical records in all patients with known COPD
   Baseline severity of COPD as measured by FEV1
   Hospital admissions during the previous 12 months
   Baseline therapy (inhaled long-acting beta agonist, long-acting anticholinergics, inhaled corticosteroid and/or supplemental oxygen)
   Presence of associated diseases such as diabetes, hypertension, ischemic heart disease and/or valve disease, cor pulmonale, peptic ulcer disease, psychiatric disorders, rheumatic disease, history of stroke or deep vein thrombosis, and others needed to determine the Charlson Comorbidity Index
   Social support and level of functional dependency
Following discharge home from the ED (1, 7, and 60 days post-discharge)
   General health status, from response to question 1 of the Short Form 36 (SF-36) questionnaire[16], degree of dyspnea, based on the Medical Research Council Dyspnea Index[17], and physical activity level (based on a scale employed previously in various studies at 1, 7, and at 60 days [18].
   Quality of life, measured by the EuroQol-5D questionnaire at 1, 7, and at 60 days [19, 20].
   Charlson Comorbidity Index[15]
   Medication use
   Response to medications
   Need for supplemental oxygen
   Visits to the patient's primary care physician, subsequent ED visits or hospital readmissions
   Death, complications, presence of other symptoms
   Level of social support
   Level of functional dependency